ARTICLE | Clinical News
Bosutinib regulatory update
October 4, 2010 7:00 AM UTC
The EC granted Orphan Drug designation for Pfizer's bosutinib to treat chronic myelogenous leukemia (CML). The dual inhibitor of BCR-ABL and Src kinase is in Phase III testing for the indication. ...